Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial
Pippa Oakeshott, Sally Kerry, Adamma Aghaizu, Helen Atherton, Sima Hay, David Taylor-Robinson, Ian Simms, Phillip Hay, Pippa Oakeshott, Sally Kerry, Adamma Aghaizu, Helen Atherton, Sima Hay, David Taylor-Robinson, Ian Simms, Phillip Hay
Abstract
Objective: To determine whether screening and treating women for chlamydial infection reduces the incidence of pelvic inflammatory disease over the subsequent 12 months.
Design: Randomised controlled trial.
Setting: Common rooms, lecture theatres, and student bars at universities and further education colleges in London.
Participants: 2529 sexually active female students, mean age 21 years (range 16-27).
Intervention: Participants completed a questionnaire and provided self taken vaginal swabs, with follow-up after one year. Samples were randomly allocated to immediate testing and treatment for chlamydial infection, or storage and analysis after a year (deferred screening controls).
Main outcome measure: Incidence of clinical pelvic inflammatory disease over 12 months.
Results: Baseline prevalence of chlamydia was 5.4% (68/1254) in screened women and 5.9% (75/1265) in controls. 94% (2377/2529) of women were followed up after 12 months. The incidence of pelvic inflammatory disease was 1.3% (15/1191) in screened women compared with 1.9% (23/1186) in controls (relative risk 0.65, 95% confidence interval 0.34 to 1.22). Seven of 74 control women (9.5%, 95% confidence interval 4.7% to 18.3%) who tested positive for chlamydial infection at baseline developed pelvic inflammatory disease over 12 months compared with one of 63 (1.6%) screened women (relative risk 0.17, 0.03 to 1.01). However, most episodes of pelvic inflammatory disease occurred in women who tested negative for chlamydia at baseline (79%, 30/38). 22% (527/2377) of women reported being tested independently for chlamydia during the trial.
Conclusion: Although some evidence suggests that screening for chlamydia reduces rates of pelvic inflammatory disease, especially in women with chlamydial infection at baseline, the effectiveness of a single chlamydia test in preventing pelvic inflammatory disease over 12 months may have been overestimated. Trial registration ClinicalTrials.gov NCT00115388.
Conflict of interest statement
Competing interests: All authors have completed the unified competing interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare (1) no financial support for the submitted work from anyone other than their employer; (2) no financial relationships with commercial entities that might have an interest in the submitted work; (3) no spouses, partners, or children with relationships with commercial entities that might have an interest in the submitted work; and (4) no non-financial interests that may be relevant to the submitted work.
Figures
References
- Centers for Disease Control. Sexually transmitted diseases treatment guidelines. MMWR 2006;55:56-7.
- European Centre for Disease Prevention and Control. Chlamydia control in Europe. ECDC, 2009.
- National Institute for Health and Clinical Excellence. Revised rapid review of evidence for the effectiveness of screening for genital chlamydia infection in sexually active young women and men. NICE, 2006.
- Scholes D, Stergachis A, Heidrich F, Andrilla H, Holmes K, Stamm W. Prevention of pelvic inflammatory disease by screening for cervical chlamydia infection. N Engl J Med 1996;334:1362-6.
- Abter E, Mahmud M. Screening for chlamydia to prevent pelvic inflammatory disease. N Engl J Med 1996;335:1531.
- Sellors J, Paavonen J. Screening to prevent pelvic inflammatory disease. N Engl J Med 1996;335:1531-2.
- Pittrof R. Screening for chlamydia to prevent pelvic inflammatory disease. N Engl J Med 1996;335:1532.
- Low N, Bender N, Nartey L, Shang A, Stephenson J. Effectiveness of chlamydia screening: systematic review. Int J Epidemiol 2009;38:435-48.
- Ostergaard L, Andersen B, Moller JK. Home sampling versus conventional swab sampling for screening of Chlamydia trachomatis in women: a cluster randomised 1-year follow-up study. Clin Infect Dis 2000;31:951-7.
- Low N, Egger M, Sterne JAC, Harbord R, Ibrahim F, Lindblom B, et al. Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women’s Cohort study. Sex Transm Infect 2006;82:212-8.
- Peterman T, Gottlieb S, Berman S. Commentary: Chlamydia trachomatis screening—what are we trying to do? Int J Epidemiol 2009;38:449-51.
- Simms I, Horner PJ. Has the incidence of pelvic inflammatory disease following chlamydia infection been overestimated? Int J STD AIDS 2008;18:285.
- Oakeshott P, Kerry S, Atherton H, Aghaizu A, Hay S, Taylor-Robinson D, et al. Community-based trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (Prevention of Pelvic Infection) trial. Trials 2008;9:73.
- Ivaz S, Dean S, Hay P, Hay S, Kerry S, Oakeshott P. Lessons learned from recruiting young female students to a randomised controlled trial of chlamydia screening. Fam Pract 2006;23:188-91.
- Atherton H, Banks D, Hay P, Kerry S, Simms I, Oakeshott P. Recruitment of young women to a trial of chlamydia screening—as easy as it sounds? Trials 2007;8:41.
- Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation 36. J Clin Microbiol 1991;29:297-301.
- Oakeshott P, Hay P, Hay S, Steinke F, Rink E, Kerry S. Association between bacterial vaginosis or chlamydial infection and miscarriage before 16 weeks’ gestation: prospective community based cohort study. BMJ 2002;325:1334-6.
- Hager D, Eschenbach D. Criteria for diagnosis and grading of salpingitis. Obstet Gynecol 1983;61:113-4.
- Ness RB, Hillier SL, Kip K, Soper D, Stamm CA, McGregor JA, et al. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol 2004;104:761-9.
- Miettinen OS, Nurminen M. Comparative analysis of two rates. Stat Med 1985;4:213-26.
- Schachter J, Chernesky MA, Willis DE, Fine PM, Martin DH, Fuller D, et al. Vaginal swabs are the specimens of choice when screening for Chlamydia trachomatis and Neisseria gonorrhoeae: results from a multicenter evaluation of the APTIMA assays for both infections 1. Sex Transm Dis 2005;32:725-8.
- Ness R, Soper D, Holley RL, Peipert J, Randall MD, Sweet R, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) randomised trial. Am J Obstet Gynecol 2002;186:929-37.
- Simms I, Rogers P, Charlett A. The rate of diagnosis and demography of pelvic inflammatory disease in general practice: England and Wales. Int J STD AIDS 1999;10:448-51.
- Adams EJ, Turner K, Edmunds WJ. The cost effectiveness of opportunistic chlamydia screening in England. Sex Transm Inf 2007;83:267-75.
- Low N, Ward H. Focus on chlamydia. Sex Transm Inf 2007;83:251-2.
- Gaydos CA, Wright C, Wood BJ, Waterfield G, Hobson S, Quinn TC. Chlamydia trachomatis reinfection rates among female adolescents seeking rescreening in school-based health centers. Sex Transm Dis 2008;35:233-7.
Source: PubMed